Companies> People>Robert Stern

Micrus Endovascular Board of Directors Names CEO John Kilcoyne Chairman and Promotes Robert Stern to President
SAN JOSE, Calif., Sep 24, 2007 (BUSINESS WIRE) --

Micrus Endovascular Corporation (NASDAQ:MEND) today announced that its board of directors has named John Kilcoyne to the position of Chairman and has promoted Robert Stern to President and to the newly created position of Chief Operating Officer. Mr. Kilcoyne, who had served as Micrus' President, Chief Executive Officer and Director since 2004, will continue to serve as the Company's CEO. Mr. Stern, who had served as Executive Vice President and Chief Financial Officer since 2004, will continue to oversee the Company's financial operations until a new CFO is named. Michael Henson, Micrus' former Chairman, will continue to serve as a Director.

"Micrus is well positioned to continue building our business by executing on our strategy to introduce a full line of differentiated hemorrhagic and ischemic stroke products that offer clinical advantages, while pursuing geographic expansion. Our board believes that this is the appropriate time to expand our management infrastructure to support our growth strategy," said Mr. Kilcoyne. "In addition to his financial leadership, Bob has been instrumental in executing our strategy by implementing effective business management processes, and leading our technology licensing and acquisition teams. With his well-deserved promotion, Bob will focus on managing operational activities and improving the integration of our product and clinical development programs, while driving further efficiencies in manufacturing. In my new role, I will continue to oversee our strategic direction and interaction with the financial community; while increasing my visibility and support of our sales and marketing efforts in North America, Europe and Asia," said Mr. Kilcoyne.

"Micrus is grateful to Mike for his many years of service as Chairman and we look forward to continuing to benefit from his guidance as we pursue further growth through geographic expansion and innovative product introductions for treatment in both the ischemic and hemorrhagic stroke markets," Mr. Kilcoyne added.

About Micrus Endovascular Corporation

Micrus develops, manufactures and markets both implantable and disposable medical devices used in the treatment of neurovascular diseases. Micrus products are used by interventional neuroradiologists and neurosurgeons primarily to treat cerebral aneurysms responsible for hemorrhagic stroke, a significant cause of death worldwide. The Micrus product line enables physicians to gain access to the brain in a minimally invasive manner through the vessels of the circulatory system. Micrus' proprietary, three-dimensional microcoils are unique in that they automatically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells accessory devices and products used in neurovascular procedures. For more information, visit www.micruscorp.com.

No additional information has been added yet. Add a LinkedIn URL.